The drug manufacturer dossier provided indications and hints of an added benefit of simeprevir when the patients infected with hepatitis C virus (HCV) genotype 1 have been untreated before or have relapsed after initially successful treatment. It is not possible to rate the extent of added benefit, however…
“Historically, scientists haven’t targeted the proteins in cancer cells that are involved in gene splicing,” said Zefeng Wang, PhD, associate professor in the department of pharmacology and senior author of the Cancer Cell paper. “This is a whole new ballgame in terms of gene regulation in cancer.” There are approximately 25,000 genes in the human genome — the same amount as in a fruit fly. But in humans, these genes are spliced together in different ways to create various kinds of messenger RNA to produce the many different proteins humans require…
“Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)” was accepted as a rapid publication and published online this month by the Journal of Clinical Oncology. It will come out in print in September. Because of its rapid growth rate, many women with triple-negative breast cancer receive chemotherapy to try to shrink it before undergoing surgery. With the standard treatment, the cancer is eliminated from the breast and lymph nodes in the armpit before surgery in about one third of women…
“There have been some concerns that one of the reasons why breast cancer may be more common in developed countries compared with developing countries is differences in bra-wearing patterns,” said Lu Chen, MPH, a researcher in the Public Health Sciences Division at Fred Hutchinson Cancer Research Center and a doctoral student in the Department of Epidemiology at the University of Washington School of Public Health. “Given how common bra wearing is, we thought this was an important question to address. …
Moritz F. Kircher and colleagues at Memorial Sloan Kettering Cancer Center point out that malignant brain tumors, particularly the kind known as glioblastoma multiforme (GBM), are among the toughest to beat…
These interim results of the 5-year Phase II clinical trial using the experimental regimen are being presented at the Breast Cancer Symposium 2014 in San Francisco by Anthony E. Dragun, M.D., vice chair and associate professor of radiation oncology at the University of Louisville. Dragun, a radiation oncologist with University of Louisville Physicians, launched the trial three years ago at UofL’s James Graham Brown Cancer Center, a part of KentuckyOne Health and the only site offering the experimental regimen in the United States…
Endoscopic biopsy of the lymph nodes is a minimally invasive, non-surgical intervention that has recently begun to be used to stage lung cancer. The study conducted by Dr…
“The take-home message of the study is that we have found a way to target breast cancer metastasis through a pathway regulated by an enzyme,” said lead author Xuefeng Wu, PhD, a postdoctoral researcher at UC San Diego. The enzyme, called UBC13, was found to be present in breast cancer cells at two to three times the levels of normal healthy cells. Although the enzyme’s role in regulating normal cell growth and healthy immune system function is well-documented, the study is among the first to show a link to the spread of breast cancer…
In a survey of around 2,200 women, Cancer Research UK scientists at University College London (UCL) found that 64 per cent felt they fully understood the information given about overdiagnosis — the chance that screening will pick up cancers that would never have gone on to cause any harm — by the National breast screening programme. Information about overdiagnosis has only been included in the NHS breast screening invitation leaflets since late 2013, meaning that overdiagnosis is likely to be a new concept for many people. But despite uncertainty over the information they were given, intentions to attend breast screening remained high, with only seven per cent of women saying they would be less likely to attend screening after receiving the overdiagnosis information…
In a survey of around 2,200 women, Cancer Research UK scientists at University College London (UCL) found that 64 per cent felt they fully understood the information given about overdiagnosis — the chance that screening will pick up cancers that would never have gone on to cause any harm — by the National breast screening programme. Information about overdiagnosis has only been included in the NHS breast screening invitation leaflets since late 2013, meaning that overdiagnosis is likely to be a new concept for many people. But despite uncertainty over the information they were given, intentions to attend breast screening remained high, with only seven per cent of women saying they would be less likely to attend screening after receiving the overdiagnosis information. …